RT Journal Article
SR Electronic
T1 Structural variants linked to Alzheimer’s Disease and other common age-related clinical and neuropathologic traits
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.12.24311887
DO 10.1101/2024.08.12.24311887
A1 Vialle, Ricardo A
A1 de Paiva Lopes, Katia
A1 Li, Yan
A1 Ng, Bernard
A1 Schneider, Julie A
A1 Buchman, Aron S
A1 Wang, Yanling
A1 Farfel, Jose M
A1 Barnes, Lisa L
A1 Wingo, Aliza P
A1 Wingo, Thomas S
A1 Seyfried, Nicholas T
A1 De Jager, Philip L
A1 Gaiteri, Chris
A1 Tasaki, Shinya
A1 Bennett, David A
YR 2024
UL http://medrxiv.org/content/early/2024/08/13/2024.08.12.24311887.abstract
AB Advances have led to a greater understanding of the genetics of Alzheimer’s Disease (AD). However, the gap between the predicted and observed genetic heritability estimates when using single nucleotide polymorphisms (SNPs) and small indel data remains. Large genomic rearrangements, known as structural variants (SVs), have the potential to account for this missing genetic heritability. By leveraging data from two ongoing cohort studies of aging and dementia, the Religious Orders Study and Rush Memory and Aging Project (ROS/MAP), we performed genome-wide association analysis testing around 20,000 common SVs from 1,088 participants with whole genome sequencing (WGS) data. A range of Alzheimer’s Disease and Related Disorders (AD/ADRD) clinical and pathologic traits were examined. Given the limited sample size, no genome-wide significant association was found, but we mapped SVs across 81 AD risk loci and discovered 22 SVs in linkage disequilibrium (LD) with GWAS lead variants and directly associated with AD/ADRD phenotypes (nominal P < 0.05). The strongest association was a deletion of an Alu element in the 3’UTR of the TMEM106B gene. This SV was in high LD with the respective AD GWAS locus and was associated with multiple AD/ADRD phenotypes, including tangle density, TDP-43, and cognitive resilience. The deletion of this element was also linked to lower TMEM106B protein abundance. We also found a 22 kb deletion associated with depression in ROSMAP and bearing similar association patterns as AD GWAS SNPs at the IQCK locus. In addition, genome-wide scans allowed the identification of 7 SVs, with no LD with SNPs and nominally associated with AD/ADRD traits. This result suggests potentially new ADRD risk loci not discoverable using SNP data. Among these findings, we highlight a 5.6 kb duplication of coding regions of the gene C1orf186 at chromosome 1 associated with indices of cognitive impairment, decline, and resilience. While further replication in independent datasets is needed to validate these findings, our results support the potential roles of common structural variations in the pathogenesis of AD/ADRD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work has been supported the following National Institute on Aging (NIA) grants: P30AG10161 (DAB), P30AG72975 (JAS), R01AG15819 (DAB), R01AG17917 (DAB), U01AG46152 (PLD, DAB), U01AG61356 (PLD, DAB), R01AG22018 (LLL), U01AG079847 (CG). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ROS and MAP studies were approved by an Institutional Review Board (IRB) of Rush University Medical Center, Chicago, IL. All participants agreed to annual clinical evaluation and organ donation at death. Each participant signed an informed consent form and an Anatomical Gift Act (AGA) for research purposes.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll SV site frequency data and complete nominal summary statistics for all phenotypes tested are publicly available on GitHub (https://github.com/RushAlz/ADRD_SV_GWAS). ROS/MAP resources, including individual-level genotyping and phenotypic data can be requested at https://www.radc.rush.edu.